StemCell Therapy

Thursday, February 9, 2017 5:11 PM UTC

CAMBRIDGE, Mass., Feb. 09, 2017 -- Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific cancer models for challenging tumors, today announced the formation of a strategic partnership withAMS Biotechnology (AMSBIO). As part of the agreement, AMSBIO will distribute, market and sell Cellaria cell models and culture media throughoutEurope.The partnership enables Cellaria to better meet growing demand for its products outside the US.

Cellaria's unique patient-specific cell models and cell culture media products expand the current offering AMSBIO has for physiologically relevant cell culture products for drug discovery and other life science applications. Late in 2016, Cellaria announced the availability of new models for High Grade Serous and Endometriod Ovarian Cancer and an ER-positive breast model.

AMSBIOis a premier provider of quality life science research reagents and services helping customers develop innovative methods, processes, products and medicines. As a leading provider of scaffolds, matrices, kits and proteins for growing and screening spheroids and organoids, AMSBIO has contributed totheaccelerationof discovery programs in medical research.

Alex Sim, managing director at AMSBIO said, "The new partnership with Cellaria expands our existing portfolio by introducing patient-derived cancer models;allowing customers to conduct research and drug discoveryinitiatives to advanceprecision medicine.

"The unique value of our patient-specific cell models makesAMSBIOan ideal partner for Cellaria," said David Deems, chief executive officer at Cellaria. "Our products will expand theAMSBIOcancer product portfolio, and their technical expertise will enable them to support Cellaria's customers throughout Europe."

About Cellaria

Cellaria creates breakthrough oncology models that reflect the unique nature and complexity of a tumor. Using these informative models, cancer researchers are better able to select promising compounds and work towards personalized approaches that would enable physicians to identify the most effective treatment for each patient's needs. Cellaria's innovative products help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cancer cure. For more information, visitwww.cellariabio.comor to learn more about our cell models.

Human Life Could Be Extended Indefinitely, Study Suggests

Goosebumps, tears and tenderness: what it means to be moved

Are over-the-counter painkillers a waste of money?

Does an anomaly in the Earth's magnetic field portend a coming pole reversal?

Immunotherapy: Training the body to fight cancer

Do vegetarians live longer? Probably, but not because they're vegetarian

Could a contraceptive app be as good as the pill?

Some scientific explanations for alien abduction that aren't so out of this world

Society actually does want policies that benefit future generations

Six cosmic catastrophes that could wipe out life on Earth

Big Pharma Starts Using Cannabis For Making Drugs In Earnest

Do you need to worry if your baby has a flat head?

Here is the original post:
Cellaria Forms Strategic Partnership with AMS Biotechnology ... - EconoTimes

This entry was posted on February 10, 2017 at 6:43 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |